EU regulator starts safety review of CAR-T cancer cell therapies Ruchika Sharma15 Jan 2024 9:00 AM ISTThe European Union's drug watchdog has said it had started a review into the safety risks associated with cancer cell therapies made by companies such...
USFDA approves label update for Kite's Yescarta CAR T-Cell Therapy to include overall survival data Ruchika Sharma26 Dec 2023 12:00 PM ISTSanta Monica: Kite, a Gilead Company has announced that the U.S. Food and Drug Administration (FDA), has approved a label update for Yescarta...
Gilead Kite declares positive trial results of T-cell Therapy Yescarta in Relapsed/Refractory Large B-cell Lymphoma Ruchika Sharma19 Sept 2023 1:30 PM ISTSanta Monica: Kite, a Gilead Company has announced results from the Phase 2 ALYCANTE study, led and sponsored by the French collaborative group...
Kite announces completion of marketing authorization transfer for Yescarta CAR T-cell therapy in Japan Ruchika Sharma25 Jun 2023 2:30 PM ISTSanta Monica: Kite Pharma, Inc., a Gilead Company, has announced that the Marketing Authorization in Japan for Yescarta (axicabtagene...
Kite Pharma, Daiichi Sankyo revise YESCARTA CAR T-Cell Therapy licensing agreement Ruchika Sharma11 Dec 2022 2:15 PM ISTTokyo: Kite Pharma, Inc., a Gilead Company, (hereafter Kite), and Daiichi Sankyo Co., Ltd. have jointly announced the revision of their 2017...
US Supreme Court rejects Bristol Myers cancer drug Yescarta patent fight with Gilead Sciences Ruchika Sharma8 Nov 2022 4:30 PM ISTA Gilead spokesperson said the company was pleased with the Supreme Court's decision, which has "effectively ended" the dispute.
